PROTAC EZH2 Degrader-9
PROTAC EZH2 Degrader-9 is orally active EZH2 PROTAC degrader degrading EZH2 via the ubiquitin-proteasome pathway. PROTAC EZH2 Degrader-9 downregulates PRC2 core subunits and potent inhibition of H3K27me3 without affecting common CRBN neosubstrates while it was selective over GSp'T1 and ikZF1/3. PROTAC EZH2 Degrader-9 exhibits potent antiproliferative activity against multiple cancer cell lines by inducing cell cycle and apoptosis. PROTAC EZH2 Degrader-9 reverses PRC2-mediated gene silencing and inhibiting EZH2 non-catalytic target gene activation. PROTAC EZH2 Degrader-9 can be used for leukemia, lymphoma, and non-small cell lung cancer research.
(Pink: EZH2 ligand (HY-78694); Blue: Cereblon ligand (HY-W087383); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 2978620-84-5
- Formula: C51H59N7O7
- Molecular Weight:882.06
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
EZH2 |
In Vitro
PROTAC EZH2 Degrader-9 (compound 5g) (0-10 μM, 0-48 h) induces the degradation of EZH2 in dependent on the ubiquitin–proteasome system and the binding to the E3 ligase CRBN in MV4–11 cells[1].
PROTAC EZH2 Degrader-9 (72 h) has antiproliferative activity in several cancer, including MV4–11 and MOLM-13 (leukemia), SU-DHL-4 and SU-DHL-6 (large B-cell lymphoma), A549, NCI-H1299, and NCI-H1703 (small cell lung cancer) with IC50s of 2.22, 2.60, 6.35, 9.23, 19.26, 4.41, and 6.35 μM, respectively, exhibits a significant negative correlation with the expression of EZH2 (Pearson r = −0.860, p = 0.013) and CRBN (Pearson r = −0.726, p = 0.049) [1].
PROTAC EZH2 Degrader-9 (10 μM, 24 h) exerts antiproliferative activities by degrading EZH2 and other PRC2 subunits in NCI-H1299, NCI-H1703, MOLM-13, and A549 cells[1].
PROTAC EZH2 Degrader-9 (10 μM, 72 h) induces 1,314 differentially expressed genes with 657 genes up-regulated and 657 genes downregulated, impacts several biological processes, including DNA repair, mitotic cell cycle, and G2/M transition of mitotic cell cycle, enriches differentially expressed genes in cancer-related pathways, particularly those governing the cell cycle, cause negative enrichment in the G2/M checkpoint pathway, and positive enrichment in the apoptosis pathway[1].
PROTAC EZH2 Degrader-9 (0.12-10 μM, 24 h and 72 h) causes cell cycle arrested in the G0/G1 phase, preventing progression into S and G2/M phases and dose-dependently induces apoptosis in MV4–11 cells[1].
PROTAC EZH2 Degrader-9 (1-10 μM, 72 h) alters gene expressions that are regulated by EZH2 catalytic and non-catalytic activities in MV4–11 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4–11 cells
-
Concentration:0, 0.06, 0.13, 0.25, 0.5, 1.0, 3.0 and 10 μM
-
Incubation Time:0, 0.5, 1, 2, 4, 8, 24, 48 h
-
Result:Decreased PRC2 levels with 10 μM at different durations.
Degraded EZH2, EED, SUZ12, and RbAp46 protein levels with 10 μM for 24 and 48 h.
Inhibited the expression of H3K27me3 at 10 μM 24 h, and achieved an almost complete elimination with 10 μM for 48 h.
Had a minimal impact on EZH2 at low concentrations of ≤ 0.25 μM h with different durations for 24 h.
Induced the degradation of all PRC2 core subunits (EZH2, EED, SUZ12, and RbAp46) at higher concentrations.
Observe no obvious changes in protein levels of GSPT1, IKZF1 or IKZF3 with different concentration for 24 h.
Exhibited no obvious effects on mRNA expression levels of EZH2, EED, SUZ12, and RbAp46 at either 3 or 10 μM.
Induced degradation of EZH2 can be reversed by MLN4924.
-
Cell Line:NCI-H1299, NCI-H1703, MOLM-13, and A549 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Induced the degradation of EZH2 as well as PRC2 subunits SUZ12, EED, and RbAp46 in in NCI-H1299 and NCI-H1703 cells.
Weakly against EZH2 and decreased PRC2 subunits in MOLM-13 cells.
Had no obvious degradation effect on PRC2 subunits in A549 cells.
-
Cell Line:MV4–11 cells
-
Concentration:0.12, 0.37, 1.11, 3.33, 10 μM
-
Incubation Time:24 h
-
Result:Demonstrated a significant dose-dependent rise in cell populations at the G0/G1 phase, increased to 63.20 %, 64.61 %, 66.12 %, 69.89 %, and 73.60 % at different concentration.
-
Cell Line:MV4-11 cells
-
Concentration:1, 3 and 10 μM
-
Incubation Time:72 h
-
Result:Up-regulated the mRNA expressions of PRC2- dependent genes, including ADRB2, CDKN2A, TXINP, and TNFRSF21 in a dose-dependent manner.
Downregulated the expression of several genes known as targets of EZH2 noncanonical functions, including ARL6IP, BRIC5, CENPK, CHEK1, TACC3, TRAP, CDC25A, and E2F1.
Not affected the expression of c-Myc.
Parmacokinetics
Chemical Information
-
CAS No. 2978620-84-5
-
Molecular Weight 882.06
-
Formula C51H59N7O7
-
SMILES
O=C1CCC(C(N1)=O)N2C(C3=C(C2=O)C=C(N4CC5(CCN(CC6=CC=CC(C7=CC(C(NCC8=C(C=C(NC8=O)C)C)=O)=C(C)C(N(C9CCOCC9)CC)=C7)=C6)CC5)CC4)C=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
-
CRISPRi/CRISPRa gene-regulation editing
CRISPRi and CRISPRa use catalytically inactive Cas9, typically SpCas9 D10A/H840A, as an RNA-guided DNA-binding platform that targets genomic loci through sgRNA complementarity and an adjacent PAM without generating Cas9 nuclease-mediated DNA cleavage. CRISPRi represses transcription by recruiting dCas9 alone or dCas9 fused to repressor domains such as KRAB to promoters or transcription start site regions, while CRISPRa activates transcription by recruiting activation domains such as VP64, VPR, or SAM components to promoter-proximal regions. The primary readout is target-gene expression change, commonly measured by RT-qPCR, RNA-seq, reporter fluorescence, or protein-level assays, and the readout reflects transcriptional repression or activation at the targeted endogenous locus.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)